Comparative Pharmacology
Head-to-head clinical analysis: VEKLURY versus VISTIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: VEKLURY versus VISTIDE.
VEKLURY vs VISTIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Remdesivir is a nucleotide analog prodrug that, after intracellular metabolism, incorporates into nascent viral RNA chains causing synthesis termination and inhibition of RNA-dependent RNA polymerase (RdRp). It targets the SARS-CoV-2 RdRp with selectivity over human RNA polymerases.
Cidofovir is a nucleotide analogue that inhibits viral DNA polymerase by incorporating into viral DNA and causing chain termination, with selectivity for cytomegalovirus (CMV) DNA polymerase.
200 mg IV on Day 1, then 100 mg IV once daily for 5 to 10 days.
5 mg/kg intravenously once weekly for 2 consecutive weeks, then every other week thereafter.
None Documented
None Documented
Remdesivir: ~1 hour (parent); GS-441524: ~27 hours (terminal). Context: GS-441524 accumulation may occur with daily dosing.
Terminal elimination half-life is approximately 1.5-2 hours in patients with normal renal function. In patients with renal impairment, the half-life can extend to 5-10 hours or longer, necessitating dose adjustment based on creatinine clearance.
Renal: 10% unchanged remdesivir; 49% as metabolite GS-441524; 18% as other metabolites. Fecal: 47.5% as metabolites. Biliary: minor.
Primarily renal excretion via glomerular filtration and active tubular secretion. Approximately 90-95% of the dose is excreted unchanged in the urine within 24 hours. Biliary/fecal excretion accounts for <5%.
Category C
Category C
Antiviral
Antiviral